Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bausch Health Companies (TSE:BHC)
TSX:BHC
RESEARCH TOOLSreports
Bausch Health Companies (BHC) Stock Price & Analysis
115 Followers
BHC Stock Chart & Stats
Day’s RangeC$0 - C$0
52-Week RangeC$7.56 - C$15.43
Previous CloseC$10.68
Volume341.63K
Average Volume (3M)388.80K
Market Cap
C$4.04B
Enterprise ValueC$34.64B
Total Cash (Recent Filing)$947.00M
Total Debt (Recent Filing)$22.39B
Price to Earnings (P/E)-6.4
Beta0.84
Next Earnings
Aug 06, 2024EPS EstimateN/A
Last Dividend Ex-Date
Nov 10, 2010Dividend YieldN/A
Share Statistics
EPS (TTM)-1.67
Shares Outstanding365,411,953
10 Day Avg. Volume340,151
30 Day Avg. Volume388,798
Standard Deviation0.15
R-Squared0.08
Alpha-0.00782
Financial Highlights & Ratios
Price to Book (P/B)-0.17
Price to Sales (P/S)1.66
Price to Cash Flow (P/CF)2.10
P/FCF Ratio0.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.97
Enterprise Value/Gross Profit3.97
Enterprise Value/Ebitda-111.75
Forecast
1Y Price Target
C$14.75Price Target Upside38.14% Upside
Rating ConsensusHold
Number of Analyst Covering6
Bausch Health Companies News
PremiumCompany Announcements
Bausch Health Reports Growth and Milestones
PremiumCompany Announcements
Bausch Health Wins Patent Appeal for XIFAXANBulls Say, Bears Say
Bulls Say
Analyst OptimismAnalysts forecast a bright future for BHC with upgrades to 'Buy' and a favorable price target, signaling confidence in the company's strategic direction and potential for stock appreciation.
Financial FlexibilityBHC's manageable debt levels paired with strong financial performance provide a stable foundation for the anticipated strategic spin-off, likely to be well-received by investors.
Legal And Patent PositivesA court ruling in favor of BHC on the Xifaxan litigation clears significant legal hurdles, setting a positive tone for the company's future exclusivity and growth.
Bears Say
Company StrategyThe path and timeline to the proposed BLCO spin-off remains a key investor focus but no definitive timeline offered.
Executive MovementCFO's departure requires monitoring, even though it is likely unrelated to the company's strategic path.
Legal ChallengesThe lawsuit against Amneal Pharmaceuticals has triggered a 30-month stay of any potential FDA approval for Amneal's ANDA.
---
Options Prices
Currently, No data available
---
Ownership Overview
70.29% Insiders
7.21% Mutual Funds
4.74% Other Institutional Investors
17.76% Public Companies and
Individual Investors
BHC FAQ
What was Bausch Health Companies’s price range in the past 12 months?
Bausch Health Companies lowest stock price was C$7.56 and its highest was C$15.43 in the past 12 months.
What is Bausch Health Companies’s market cap?
Currently, no data Available
When is Bausch Health Companies’s upcoming earnings report date?
Bausch Health Companies’s upcoming earnings report date is Aug 06, 2024 which is in 94 days.
How were Bausch Health Companies’s earnings last quarter?
Bausch Health Companies released its earnings results on May 02, 2024. The company reported C$0.863 earnings per share for the quarter, missing the consensus estimate of C$0.932 by -C$0.069.
Is Bausch Health Companies overvalued?
According to Wall Street analysts Bausch Health Companies’s price is currently Undervalued.
Does Bausch Health Companies pay dividends?
Bausch Health Companies pays a Quarterly dividend of C$1.37 which represents an annual dividend yield of N/A. See more information on Bausch Health Companies dividends here
What is Bausch Health Companies’s EPS estimate?
Bausch Health Companies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bausch Health Companies have?
Bausch Health Companies has 366,796,720 shares outstanding.
What happened to Bausch Health Companies’s price movement after its last earnings report?
Bausch Health Companies reported an EPS of C$0.863 in its last earnings report, missing expectations of C$0.932. Following the earnings report the stock price went down -8.146%.
Which hedge fund is a major shareholder of Bausch Health Companies?
Among the largest hedge funds holding Bausch Health Companies’s share is Carl Icahn C. It holds Bausch Health Companies’s shares valued at 278M.
---
Bausch Health Companies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
C$14.75 (38.14% Upside)
C$14.75 (38.14% Upside)
Blogger Sentiment
Bullish
TSE:BHC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 2.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Bullish
Bullish news 75%
Bearish news 25%
Bearish news 25%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.77%
Trailing 12-Months
Company Description
Bausch Health Companies
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets.
---
BHC Company Deck
---
BHC Earnings Call
Q1 2024
0:00 / 0:00
---
BHC Revenue Breakdown
44.64% Pharmaceuticals
22.80% Devices
20.52% OTC
10.96% Branded and Other Generics
1.07% Other
---
BHC Stock 12 Months Forecast
Average Price Target
C$14.75
▲(38.14% Upside)
Technical Analysis
Best Analysts Covering BHC
1 Year
1 Year Success Rate
8/12 ratings generated profit
1 Year Average Return
+18.55%
reiterated a sell rating 2 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +18.55% per trade.
---